Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 1999

View Archived Issues

Company Profile: NeuroVir

Chromium picolinate identified as insulin assistance factor

La Jolla presents new Toleragen compound with potential to treat autoimmune blood clotting disorder

Genset signs collaboration with Johns Hopkins for schizophrenia gene identification

Roberts will distribute emergency contraceptive kit in Canada

Phase III trial results presented for Leukine in AIDS

Postmarketing studies of latanoprost support efficacy, safety of antiglaucoma agent

Microtubule disruption by T-138067 produces potent anticancer activity in MDR tumors

Cholesteryl ester transfer protein inhibitors patented by Bayer

Antiinflammatory and analgesic pyrazoles described by Fujisawa

Roche team synthesizes new series of PLA2 inhibitors

Glaxo reports kinase inhibitors especially useful for chemotherapy-induced alopecia

Vitronectin receptor antagonists from SB for osteoporosis, cancer, etc.

Cytokine-inhibitory aminotetralines synthesized and evaluated at Sigma-Tau

OraVax and Peptide Therapeutics merger completed this week

Clinical trials of OP-2000 for IBD to begin later this year

IntraDose NDA to receive fast track review by FDA

RB-2121, an anti-HIV agent directed to a novel antiretroviral target

RFS-2000 (now rubitecan) advances in clinical trials in over 10 tumor types

ONYX-015 now under clinical evaluation for chemopreventive potential

RD3-0028 is effective in treating RSV infection in mice

Periodontix announces phase I/II trial of histatin-based mouthwash for oral candidiasis

Planned accelerated full merger of Rhone-Poulenc and Hoechst moves ahead

Approvable letter for Exelon NDA issued by FDA

Company Profile: Message Pharmaceuticals

U.S. patent issues to Cytogen for PSMA-specific abtides

Tranilast evaluated in dog model of intimal hyperplasia following vascular injury

Ribi ImmunoChem: Q1 1999 highlights

DSMB approves continuation of phase III trial of Flocor in sickle cell crisis

Genzyme Molecular Oncology outlines development plans at recent analysts meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...